Roche's Vabysmo demonstrated sustained two-year efficacy in the SALWEEN study for PCV patients, showing significant vision and retinal health improvements. Over 60% of patients achieved an extended 20-week dosing interval, reducing treatment burden while maintaining a consistent safety profile. This positive clinical data reinforces Vabysmo's market position and potential for increased adoption.
Roche announced positive two-year results from its SALWEEN study for Vabysmo, a drug treating polypoidal choroidal vasculopathy (PCV), an aggressive form of nAMD. The study showed significant improvements in vision and retinal health, with over 60% of patients achieving an extended 20-week dosing interval, which substantially reduces the treatment burden. This is important because it strengthens Vabysmo's competitive profile against existing treatments, potentially leading to increased market share and revenue for Roche. For traders, this reinforces Roche's long-term growth prospects in ophthalmology, while competitors like Novartis and Regeneron might face increased pressure, though the immediate impact on them is likely neutral as this is not a new drug but rather extended data.